ArticleCancer cell international2026
PAARH suppresses Kupffer cell phagocytosis to promote tumor liver metastasis by upregulating CD47.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Metastasis is the primary cause of cancer-related mortality, with the liver being a common metastatic target organ for multiple malignancies. Kupffer cells (KCs), the liver-resident macrophages, play a crucial role in suppressing liver metastasis by phagocytosing disseminated tumor cells. However, the molecules modulating KC phagocytosis and liver metastatic progression remain poorly understood. Our previous work identified PAARH as an oncogenic factor in hepatocellular carcinoma (HCC) that correlates with poor patient prognosis. Here, we demonstrate that PAARH functions as an anti-phagocytic molecule for KCs. PAARH facilitates liver metastasis of various tumor cells by suppressing KCs phagocytosis. In vitro phagocytosis assays showed that PAARH suppresses the phagocytosis of tumor cells cultured under hypoxia by KCs. Mechanistically, PAARH recruits HIF-1α to the CD47 promoter, activating CD47 transcription under hypoxia. Consistent with this, PAARH and HIF-1α expression positively correlate with CD47 levels across multiple human tumor tissues. CD47 was identified as a phagocytosis checkpoint for KCs, mediating PAARH’s effects on phagocytosis inhibition and liver metastasis. Clinically, high PAARH and CD47 expression in tumors were associated with increased liver metastases. Our findings establish PAARH as a critical anti-phagocytic molecule for KCs through transcriptional activation of CD47 and suggest that targeting PAARH could selectively enhance the clearance of hypoxic tumor cells, offering a potential therapeutic strategy to limit liver metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.